Aducanumab: European agency rejects Alzheimer’s drug over efficacy and safety concerns
Year: 2021
Type: other
Source: BMJ
DOI: 10.1136/bmj.n3127
Author: Elisabeth Mahase
Institution: BMJ Group (United Kingdom)
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4200405478
